301301 Stock Overview
Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Yili Chuanning Biotechnology Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥13.18 |
52 Week High | CN¥13.18 |
52 Week Low | CN¥6.94 |
Beta | 0 |
1 Month Change | 38.88% |
3 Month Change | 72.06% |
1 Year Change | 43.73% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 38.30% |
Recent News & Updates
Recent updates
Shareholder Returns
301301 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 34.5% | 2.6% | 1.2% |
1Y | 43.7% | -19.6% | -12.6% |
Return vs Industry: 301301 exceeded the CN Biotechs industry which returned -21.4% over the past year.
Return vs Market: 301301 exceeded the CN Market which returned -13.2% over the past year.
Price Volatility
301301 volatility | |
---|---|
301301 Average Weekly Movement | 9.3% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 8.5% |
10% most volatile stocks in CN Market | 12.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 301301's share price has been volatile over the past 3 months.
Volatility Over Time: 301301's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 2,881 | Xuheng Deng | www.klcnsw.com |
Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid.
Yili Chuanning Biotechnology Co.,Ltd. Fundamentals Summary
301301 fundamental statistics | |
---|---|
Market cap | CN¥29.30b |
Earnings (TTM) | CN¥1.12b |
Revenue (TTM) | CN¥5.08b |
26.2x
P/E Ratio5.8x
P/S RatioIs 301301 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301301 income statement (TTM) | |
---|---|
Revenue | CN¥5.08b |
Cost of Revenue | CN¥3.40b |
Gross Profit | CN¥1.67b |
Other Expenses | CN¥554.71m |
Earnings | CN¥1.12b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.50 |
Gross Margin | 32.94% |
Net Profit Margin | 22.02% |
Debt/Equity Ratio | 23.4% |
How did 301301 perform over the long term?
See historical performance and comparison